Los puntos clave no están disponibles para este artículo en este momento.
Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options.
Palma et al. (Thu,) studied this question.